Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology

Abstract

Soluble antigens diffuse out of the brain and can thus stimulate a systemic immune response, whereas particulate antigens (from infectious agents or tumor cells) remain within brain tissue, thus failing to stimulate a systemic immune response. Immune privilege describes how the immune system responds to particulate antigens localized selectively within the brain parenchyma. We believe this immune privilege is caused by the absence of antigen presenting dendritic cells from the brain. We tested the prediction that expression of fms-like tyrosine kinase ligand 3 (Flt3L) in the brain will recruit dendritic cells and induce a systemic immune response against exogenous influenza hemagglutinin in BALB/c mice. Coexpression of Flt3L with HA in the brain parenchyma induced a robust systemic anti-HA immune response, and a small response against myelin basic protein and proteolipid protein epitopes. Depletion of CD4 + CD25+ regulatory T cells (Tregs) enhanced both responses. To investigate the autoimmune impact of these immune responses, we characterized the neuropathological and behavioral consequences of intraparenchymal injections of Flt3L and HA in BALB/c and C57BL/6 mice. T cell infiltration in the forebrain was time and strain dependent, and increased in animals treated with Flt3L and depleted of Tregs; however, we failed to detect widespread defects in myelination throughout the forebrain or spinal cord. Results of behavioral tests were all normal. These results demonstrate that Flt3L overcomes the brain's immune privilege, and supports the clinical development of Flt3L as an adjuvant to stimulate clinically effective immune responses against brain neo-antigens, for example, those associated with brain tumors.immune response | dendritic cells | influenza hemagglutinin | regulatory T cells | perivascular cuffs

Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice

“…tumors. Brain immune privilege could be overcome through exogenous expression of fms-like tyrosine kinase ligand 3, which resulted in DC recruitment and antigen presentation (26). Others have shown improvement in antitumor responses to DC vaccine when the cells were also given locally into the brain (27).…”

Improved Adeno-associated Viral Gene Transfer to Murine Glioma

“…The absence of conventional lymphatic drainage, low levels of constitutive expression of MHC class I and II molecules, production of powerful immunosuppressive factors such as TGF-β or other factors that activate regulatory T cells, and scarcity of dendritic cells all contribute to immune hypo-responsiveness in the brain [55]. Furthermore, during tumorigenesis, brain tumors develop powerful means of down-regulating immune responses, which may be elicited against the tumor [56].…”

Adenoviral vector-mediated gene therapy for gliomas: coming of age

“…The missing cell type was postulated to be the dendritic cells, and we developed the direct Ad-mediated delivery of Flt3L to the brain as a way to attract dendritic cells to the brain, and thus, reconstruct the immune circuits left behind during the co-evolution of the brain and the immune system (58,89). Regarding the safety of this approach, examination of all our models has failed to show the induction of brain autoimmunity (89,120). In summary, the transduction characteristics of adenoviral vectors, and their overall safety profile, added to their capacity to achieve high levels of transgene expression in the brain have made them the vector of choice to treat GBM.…”